Key result
Deferred outpatient CRT linked to ~44% lower all-cause mortality compared to inpatient implantation.
Why the study?
The role of CRT during heart failure hospitalization is uncertain because hospitalized patients were routinely excluded from landmark trials, despite CRT implantation during hospitalization being common.
Does inpatient CRT implantation during heart failure hospitalization compared to deferred outpatient CRT affect long-term survival and heart failure re-hospitalization?
Cohort
Does inpatient CRT implantation during heart failure hospitalization compared to deferred outpatient CRT affect long-term survival and heart failure re-hospitalization?
Answers are grounded in this paper and cite their sources.
Patients receiving inpatient CRT during a heart failure hospitalization represent a higher-risk phenotype with worse long-term survival and higher re-hospitalization rates compared to those receiving deferred outpatient CRT.
BACKGROUND: The role of cardiac resynchronization therapy (CRT) during hospitalization for heart failure (HFH) is uncertain, because hospitalized patients were routinely excluded from landmark CRT trials. Despite this, CRT implantation during HFH is common. This study aimed to compare the clinical profiles and post-implantation outcomes of patients undergoing inpatient CRT during HFH with those receiving deferred outpatient CRT after HFH. METHODS: Institutional CRT data were linked with the National Heart Failure Audit from January 2014 to December 2024. Patients were stratified by inpatient or outpatient CRT implantation setting. Baseline characteristics, HFH within one year of CRT and long-term survival were compared. Multivariable Cox proportional hazards modelling assessed the association between implantation setting and mortality. RESULTS: , p = 0.01), more ischemic cardiomyopathy (40.8% vs. 18.9%, p = 0.01), less left bundle branch block (36.9% vs. 51.1%, p = 0.04), and more HF hospitalizations in the year before CRT (1.12±0.87 vs. 0.84±0.86, p = 0.01). The risk of ≥1 HF re-hospitalization within one year of CRT was higher (23.1% vs. 7.8%; p = 0.004) in the inpatient group. Median survival after CRT was 2.9 years shorter for the inpatient group (1192 vs. 2262 days, p = 0.003). After adjustment, deferred outpatient CRT remained associated with lower all-cause mortality (HR 0.56, 95% CI 0.35-0.88, p = 0.01). CONCLUSION: Patients selected for inpatient CRT during HFH represent a clinically distinct, higher-risk subgroup with worse post-implant outcomes. Prospective studies are needed to optimize patient selection for inpatient CRT.
No takes yet. Share an insight, caveat, or question.
Rees et al. (2026) conducted a cohort in Heart failure. Deferred outpatient cardiac resynchronization therapy vs. Inpatient cardiac resynchronization therapy was evaluated on All-cause mortality (HR 0.56, 95% CI 0.35-0.88, p=0.01). Deferred outpatient cardiac resynchronization therapy was associated with lower all-cause mortality compared to inpatient implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: